Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
1.
Gan To Kagaku Ryoho ; 49(1): 97-99, 2022 Jan.
Article in Japanese | MEDLINE | ID: mdl-35046374

ABSTRACT

A 70-year-old woman underwent a partial mastectomy with preoperative diagnosis of phyllodes tumor. Histopathological examination of the resected specimen revealed noninvasive ductal carcinoma of up to 20 mm in the phyllodes tumor. We note the possibility of a situation in which a phyllodes tumor is accompanied by cancer, and detailed pathological examination is necessary.


Subject(s)
Breast Neoplasms , Carcinoma, Ductal, Breast , Phyllodes Tumor , Aged , Breast Neoplasms/surgery , Carcinoma, Ductal, Breast/surgery , Female , Humans , Mastectomy , Mastectomy, Segmental , Phyllodes Tumor/surgery
2.
Breast Cancer ; 27(5): 954-962, 2020 Sep.
Article in English | MEDLINE | ID: mdl-32301097

ABSTRACT

BACKGROUND: Chemotherapy-induced taste and smell alterations in cancer patients are associated with multiple adverse effects, namely, malnutrition, weight loss, and a diminished quality of life. The aim of this prospective study was to identify the incidence of taste alterations following epirubicin and cyclophosphamide (EC) chemotherapy in patients with breast cancer without previous history of cancer or chemotherapy. METHODS: Forty-one patients undergoing EC chemotherapy for breast cancer at Tokai University Hospital were included. A subjective (questionnaire) and an objective (filter paper disk method) assessment for 5 basic tastes were administered on day 4 post-chemotherapy and immediately before the subsequent cycle of chemotherapy for each cycle, in addition to an olfactory evaluation and oral examination. The correlation between subjective and objective taste alterations and factors influencing these alterations were analyzed by statistical means. RESULTS: The mean incidence of subjective taste alteration on the 4th day after chemotherapy was 53%. In each of the 4 cycles, taste alterations decreased to about 9.0% immediately before the next cycle. A significant correlation between subjective and objective assessments was seen only for salty taste, suggesting important differences in subjective versus objective assessment outcomes. A multivariate analysis indicated that age and body surface area influenced taste alterations. CONCLUSIONS: EC chemotherapy induced taste alterations in more than 50% of patients, which decreased to less than 10% immediately before the next chemotherapy cycle. A combination of objective and subjective assessments is essential to evaluate taste alterations induced by EC chemotherapy. These could be used in routine clinical practice.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/adverse effects , Breast Neoplasms/drug therapy , Olfaction Disorders/epidemiology , Taste Disorders/epidemiology , Taste Threshold/drug effects , Adult , Aged , Cyclophosphamide/adverse effects , Epirubicin/adverse effects , Female , Humans , Incidence , Middle Aged , Olfaction Disorders/chemically induced , Olfaction Disorders/diagnosis , Prospective Studies , Quality of Life , Self Report/statistics & numerical data , Smell/drug effects , Taste Disorders/chemically induced , Taste Disorders/diagnosis
3.
Int J Clin Oncol ; 23(6): 1038-1045, 2018 Dec.
Article in English | MEDLINE | ID: mdl-30047071

ABSTRACT

BACKGROUND: There are few quality of life (QOL) studies that have focused on the experiences of oral cancer patients. Therefore, the present study aimed to investigate how the QOL for patients with oral cancer changed perioperatively. METHODS: Eighty-three participants undergoing radical therapy completed assessments of QOL at pre-treatment, treatment completion, and 1-, 3-, and 6-months post-treatment. The Japanese version of the FACT-H&N, comprising the subscales of "physical well-being (PWB)," "social/family well-being (SWB)," "emotional well-being (EWB)," "functional well-being (FWB)," and "additional head- and neck-specific concerns(HN)" was used to assess QOL. There were two study groups: those who required reconstructive surgery (r+, 31 patients) and those who did not (r-, 52 patients). RESULTS: The FACT-H&N, PWB, FWB, and HN, were lowest at treatment completion due to declines; then, it showed significant improvement over time (p < 0.05). SWB was the highest at the completion of treatment, and thereafter decreased significantly until 3 months after treatment (p < 0.05). EWB was the lowest before treatment but improved over time (p < 0.01). HN was significantly lower at 6 months after treatment than before treatment (p < 0.05). The QOL of the r+ group was significantly lower than that of the r- group (p < 0.01). CONCLUSIONS: The treatment-associated declines in subscale area may be compensated for by gains in other subscale areas. Psychological support is better introduced prior to cancer treatment. As it is often difficult to recover from declines in HN functioning subscale, strategies that promote compensation in other areas must be explored. Clinicians should become thoroughly familiar with how patients' QOL changes over time and provide holistic treatments that honor patients' autonomy.


Subject(s)
Mouth Neoplasms/surgery , Perioperative Period , Quality of Life , Adult , Aged , Aged, 80 and over , Female , Health Status , Humans , Longitudinal Studies , Male , Middle Aged , Mouth Neoplasms/pathology , Mouth Neoplasms/psychology , Prospective Studies , Surveys and Questionnaires , Treatment Outcome , Young Adult
4.
Mol Clin Oncol ; 8(1): 68-72, 2018 Jan.
Article in English | MEDLINE | ID: mdl-29399347

ABSTRACT

Lateral retropharyngeal lymph node (LRPLN) is located between the internal carotid artery and the prevertebral muscles. Metastasis to the LRPLN is frequent in nasopharyngeal cancer, but is rare in oral cancer. The prognosis of patients with oral cancer with LRPLN metastasis is usually poor. The present study reported a patient with LRPLN metastasis from squamous cell carcinoma of the upper gingiva, who survived for >7 years. Docetaxel, cisplatin and fluorouracil (TPF) therapy was performed as induction chemotherapy and it was planned to subsequently conduct chemoradiotherapy or surgery. As the tumor only exhibited a transient response to TPF, surgery was selected. Postoperatively, only radiotherapy was performed and a favorable outcome was achieved.

6.
Tokai J Exp Clin Med ; 42(1): 19-24, 2017 Apr 20.
Article in English | MEDLINE | ID: mdl-28413867

ABSTRACT

OBJECTIVE: The aim of this study was to assess the feasibility and safety profile of concurrent chemoradiotherapy with cisplatin in Japanese patients with postoperative high-risk oral cancer. METHODS: Patients with high-risk pathological features were selected from patients with oral squamous cell carcinoma who underwent surgery at the Department of Oral and Maxillofacial Surgery, Tokai University Hospital. Patients were given adjuvant chemoradiotherapy with tri-weekly cisplatin (100 mg/m2) (66 Gy/33 Fr), and the treatment completion rate was examined. RESULTS: A total of 27 patients were enrolled between April 2011 and December 2012, including 19 males and 8 females. The median follow-up period was 36 months, and the protocol completion rate was 81.5%. Grade 3 or higher adverse events included leukopenia in 16 patients (59.3%), anemia in 7 patients (25.9%), mucositis in 2 patients (7.4%), increased creatinine in 1 patient (3.7%), nausea in 4 patients (14.8%), and anorexia in 12 patients (44.4%). The 3-year overall survival rate was 66.7%, relapse-free survival rate was 63.0%, and locoregional control rate was 77.8%. CONCLUSION: The feasibility and safety profile of concurrent chemoradiotherapy with cisplatin in Japanese patients with postoperative high-risk oral cancer were comparable to pivotal phase III trials.


Subject(s)
Antineoplastic Agents/administration & dosage , Carcinoma, Squamous Cell/therapy , Chemoradiotherapy, Adjuvant , Cisplatin/administration & dosage , Mouth Neoplasms/therapy , Adult , Aged , Asian People , Carcinoma, Squamous Cell/surgery , Drug Administration Schedule , Feasibility Studies , Female , Humans , Male , Middle Aged , Mouth Neoplasms/surgery , Postoperative Period , Prognosis , Radiotherapy Dosage , Risk , Safety
7.
Tokai J Exp Clin Med ; 41(3): 112-7, 2016 Sep 20.
Article in English | MEDLINE | ID: mdl-27628601

ABSTRACT

We investigated whether neck dissection should be performed to prevent T1-2N0M0 tongue cancer by using the Weiss and colleague's decision tree method. The results showed that preventive neck dissection should not be recommended for T1-2N0M0 tongue cancer. However, preventive neck dissection is a suitable approach when treating tongue cancer tumors with a thickness of ≥ 4 mm.


Subject(s)
Carcinoma, Squamous Cell/surgery , Elective Surgical Procedures , Neck Dissection , Tongue Neoplasms/surgery , Aged , Analysis of Variance , Carcinoma, Squamous Cell/pathology , Carcinoma, Squamous Cell/prevention & control , Female , Humans , Male , Middle Aged , Neoplasm Staging , Retrospective Studies , Tongue Neoplasms/pathology , Tongue Neoplasms/prevention & control
SELECTION OF CITATIONS
SEARCH DETAIL